


**Amendments to the Claims:**

This claim listing will replace all prior versions and listings of claims in the application:

**Claim Listing:**

- 1-19. (Cancelled)
20. (Currently amended) An immunostimulatory oligonucleotide compound, comprising:  
an immunostimulatory dinucleotide of formula C\*pG, C\*pG\* or CpG\*, wherein C is a  
natural pyrimidine nucleoside, C\* is a non-natural pyrimidine nucleoside, G is a natural  
purine nucleoside and G\* is a non-natural purine nucleoside, wherein when the  
immunostimulatory dinucleotide is C\*pG, then C\* is selected from 5-hydroxycytosine, 5-  
hydroxymethylcytosine, N4-alkylcytosine and 4-thiouracil, and wherein p is an  
internucleotide linkage selected from the group consisting of phosphodiester,  
phosphorothioate and phosphorodithioate;  
  
a 3'-3' linkage; and  
  
one or two accessible 5' ends.
21. (Original) The immunostimulatory oligonucleotide compound of claim 20, which  
oligonucleotide comprises two accessible 5' ends.
- 22.-40. (Canceled)
41. (Previously presented) The immunostimulatory oligonucleotide compound of claim 20,  
wherein G\* is 7-deazaguanosine.
42. (Currently amended) An immunostimulatory oligonucleotide compound, comprising:an  
immunostimulatory dinucleotide of formula C\*pG, wherein C\* is a non-natural  
pyrimidine nucleoside having formula (**I**):



selected from 5-hydroxycytosine, 5-hydroxymethylcytosine, N4-alkylcytosine, and 4-thiouracil; wherein D is a hydrogen bond donor, D' is selected from the group consisting of hydrogen, hydrogen bond donor, hydrophilic group, hydrophobic group and electron donating group, A is a hydrogen bond acceptor or a hydrophilic group, X is carbon or nitrogen, and S is a pentose or hexose sugar ring, provided that the pyrimidine nucleoside of formula (I) is not cytidine or deoxycytidine, and G is a natural purine nucleoside, and wherein p is an internucleotide linkage selected from the group consisting of phosphodiester, phosphorothioate and phosphorodithioate;

a 3'-3' linkage; and

one or two accessible 5' ends.

43-45. (Canceled)

46. (Currently amended) The immunostimulatory oligonucleotide compound of claim 43 42, wherein the non-natural pyrimidine nucleoside of formula (I) comprises a non-naturally occurring sugar moiety.

47. (Previously presented) The immunostimulatory oligonucleotide compound of claim 46, wherein the non-naturally occurring sugar moiety is arabinose.

48-51. (Canceled)